JSK Biomed Showcases Mirajet: Revolutionizing Drug Delivery at 2024 Tech Innovation

JSK Biomed announced that it received strong interest from attendees and investors by participating in the '2024 Tech Innovation' technology startup event held in Singapore.

This event brings together innovative startups with advanced technologies from Asia and the global market to showcase the latest products and technologies and explore collaboration opportunities. It mainly attracts attention from industry professionals and investors worldwide in healthcare, artificial intelligence (AI), and sustainability.

Mirajet is the world's first medical device to inject medication into the skin using laser pulses. It is recognized for significantly reducing the pain and fear commonly associated with syringe use. Notably, by eliminating the need for needles, it minimizes infection risks and enables precise drug delivery, making it highly sought-after in the aesthetic medicine field.

At the event, JSK Biomed showcased Mirajet, the world's first needle-free injector. Mirajet is a medical device that employs advanced technology and uses ultra-fine laser pulses instead of needles to deliver nutrients deep into the skin. Not using needles eliminates infection risks and ensures precise drug delivery, leading to highly effective skin improvement. This has created a strong impact in the aesthetic medicine field, with export inquiries pouring in from multiple countries worldwide.

A representative from JSK Biomed stated, "Through this exhibition, we are exploring collaboration opportunities with key investors in the Asian region and establishing a foundation for overseas market entry. Given the rising demand for medical and aesthetic technologies in Southeast Asia, we anticipate that JSK Biomed's innovative products will succeed in the local market.

Meanwhile, JSK Biomed is also set to participate in the ‘2024 Korea Derma' event hosted by the Korean Dermatological Association from November 1 to 3. At this event, six dermatologists from around the world, including Korea, Japan, and the United States, will share the clinical results of Mirajet.